Argenx Believes It Might Have 'One Of The Biggest Biologics' Ever — And Shares Are SoaringInvestors Business Daily • 05/18/23
All You Need to Know About argenex SE (ARGX) Rating Upgrade to BuyZacks Investment Research • 05/09/23
argenx Reports First Quarter 2023 Financial Results and Provides Business UpdateGlobeNewsWire • 05/04/23
argenx to Report First Quarter 2023 Financial Results and Business Update on May 4, 2023GlobeNewsWire • 04/27/23
argenx: Exciting Genmab Partnership, All Eyes On Q1 Earnings And CIDP ReadoutSeeking Alpha • 04/21/23
argenx Demonstrates Commitment to Redefining Treatment Goals for Generalized Myasthenia Gravis with Multiple Presentations at American Academy of Neurology 2023 Annual MeetingGlobeNewsWire • 04/18/23
argenx and Genmab Enter Partnership to Advance Antibody Therapies in Immunology and OncologyGlobeNewsWire • 04/17/23
Genmab and argenx Enter Partnership to Advance Antibody Therapies in Immunology and OncologyGlobeNewsWire • 04/17/23
argenx Announces UK MHRA Approval of VYVGART for the Treatment of Generalized Myasthenia GravisGlobeNewsWire • 03/15/23
argenx Reports Full Year 2022 Financial Results and Provides Fourth Quarter Business UpdateGlobeNewsWire • 03/02/23
argenx to Report Full Year 2022 Financial Results and Fourth Quarter Business Update on March 2, 2023GlobeNewsWire • 02/23/23
argenx: Priority Review Voucher Goes To Waste And Why SC Efgartigimod Is ImportantSeeking Alpha • 02/06/23
argenx Announces Extraordinary General Meeting of Shareholders on February 27, 2023 to Appoint Steve Krognes as Non-Executive DirectorGlobeNewsWire • 01/16/23
argenex SE (ARGX) Upgraded to Buy: What Does It Mean for the Stock?Zacks Investment Research • 01/10/23